Phase 4 N=74 Fall Prevention in Older Adults With OAB
Overactive Bladder
Primary: Measure of Physical Activity — 1634.19 steps per day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=380 Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
Hepatitis C, Chronic
Primary: Undetectable HCV RNA (ITT Population) — 121; 233 Participants — p=<0.05
Phase 2 N=5 CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
Congenital Hyperinsulinism
Primary: Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind) — 2; 0 Participants
Phase 3 N=387 Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
Dermatitis, Atopic
Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement…
N/A N=80 PK/PD Pediatric ADHD Classroom Study
Attention Deficit Hyperactivity Disorder
Primary: Permanent Product Measure of Performance (PERMP) for Three Methylphenidate Hydrochloride Extended-release Drug Products — 66.925; 95.361; 80.621; 92.176 score on a scale
N/A N=213 Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries
Peripheral Artery Disease
Primary: Efficacy - Number of Subjects That Met Primary Patency Criteria at 12 Months — 120 Participants
N/A N=40 Testing a Neurocognitive Model of Distancing Using Transcranial Magnetic Stimulation.
Emotion Regulation · Real Versus Sham Transcranial Magnetic Stimulation (TMS)
Primary: Change in Self-reported Valence (Distancing) From Baseline to 30 Minutes Post Stimulation. — .662; .668 score on a scale — p=.019
N/A N=816 Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis
Myopia
Primary: High Contrast Visual Acuity — -0.065; -0.047 logMAR
Phase 2 N=61 Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Heptocellular Cancer · Biliary Tract Neoplasms · Liver Cancer
Primary: Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution — 8; 12; 12; 9 Participants
N/A N=210 Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)
Peripheral Arterial Disease
Primary: Change in Six-Minute Walk Performance at 12-week Follow-up — 22.2; -6.4; 28.5; -5.0 meters — p=0.052
Phase 2 N=111 Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma · Gastric Cancer
Primary: 6 Month Progression Free Survival (PFS) — 63; 53; 73 percentage of paticipants
N/A N=120 Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
Von Willebrand Disease
Primary: Incidence of Adverse Drug Reactions (ADRs) (%) — 8; 1; 1; 3 Participants
N/A N=44 Performance of Two Toric Silicone Hydrogel Contact Lenses
Astigmatism
Primary: Lens Centration — 44; 44 Participants
Phase 2 N=25 A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Trough Plasma Levels (Ctrough) of Calcitriol — 65.04; 62.53; 61.87; 61.46 Picograms Per Millilitre (pg/mL)
Phase 2 N=108 Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
Inflammation · Fibrosis
Primary: Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 12 Months — 0.14; 0.29 pg/mL